GT BIOPHARMA, INC. Fair Value Adjustment of Warrants
GT BIOPHARMA, INC. (GTBP) reported Fair Value Adjustment of Warrants of -$11.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-14
- GT BIOPHARMA, INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$11.00K.
- GT BIOPHARMA, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was $3.00K, a 95.71% decline year-over-year.
- GT BIOPHARMA, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$232.00K.
- GT BIOPHARMA, INC. fair value adjustment of warrants for fiscal 2025 was -$241.00K.
- GT BIOPHARMA, INC. fair value adjustment of warrants for fiscal 2024 was -$800.00K.
- GT BIOPHARMA, INC. fair value adjustment of warrants for fiscal 2023 was -$4.80M.
- GT BIOPHARMA, INC. fair value adjustment of warrants for fiscal 2022 was -$119.00K, a 186.23% decline from fiscal 2021.
| Period end | Fair Value Adjustment of Warrants 1 month | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 6 month as first filed | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 9 month as first filed | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$11.00K 10-Q · filed 2026-08-14 | -$8.00K derived: sum of 3 quarters · filed 2026-08-14 | -$240.00K derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2026-03-31 | -$11.00K 10-Q · filed 2026-05-15 | -$8.00K derived: sum of 2 quarters · filed 2026-05-15 | -$240.00K derived: sum of 3 quarters · filed 2026-05-15 | -$126.00K derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-12-31 | $3.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | -$229.00K derived: sum of 2 quarters · filed 2026-03-06 | -$115.00K derived: sum of 3 quarters · filed 2026-08-14 | -$241.00K 10-K · filed 2026-03-02 | |||||
| 2025-09-30 | -$232.00K 10-Q/A · filed 2026-03-06 | -$118.00K derived: sum of 2 quarters · filed 2026-08-14 | -$244.00K 10-Q/A · filed 2026-03-06 | -$174.00K derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-06-30 | $114.00K 10-Q · filed 2026-08-14 | -$12.00K 10-Q · filed 2026-08-14 | $58.00K derived: sum of 3 quarters · filed 2026-08-14 | -$37.00K derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-03-31 | -$126.00K 10-Q · filed 2026-05-15 | -$56.00K derived: sum of 2 quarters · filed 2026-05-15 | -$151.00K derived: sum of 3 quarters · filed 2026-05-15 | -$268.00K derived: sum of 4 quarters · filed 2026-05-15 | |||||
| 2024-12-31 | $70.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | -$25.00K derived: sum of 2 quarters · filed 2026-03-06 | -$142.00K derived: sum of 3 quarters · filed 2026-03-06 | -$800.00K 10-K · filed 2026-03-02 | |||||
| 2024-09-30 | -$95.00K 10-Q/A · filed 2026-03-06 | -$212.00K derived: sum of 2 quarters · filed 2026-03-06 | -$870.00K 10-Q/A · filed 2026-03-06 | -$871.00K derived: sum of 4 quarters · filed 2026-03-06 | |||||
| 2024-06-30 | -$117.00K 10-Q/A · filed 2026-03-06 | -$775.00K 10-Q/A · filed 2026-03-06 | -$776.00K derived: sum of 3 quarters · filed 2026-03-06 | -$1.26M derived: sum of 4 quarters · filed 2026-03-06 | |||||
| 2024-03-31 | -$658.00K 10-Q · filed 2025-05-15 | -$659.00K derived: sum of 2 quarters · filed 2025-05-15 | -$1.14M derived: sum of 3 quarters · filed 2025-05-15 | -$2.53M derived: sum of 4 quarters · filed 2025-05-15 | |||||
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$486.00K derived: sum of 2 quarters · filed 2025-02-21 | -$1.87M derived: sum of 3 quarters · filed 2025-02-21 | -$4.80M 10-K · filed 2025-02-21 | |||||
| 2023-09-30 | -$485.00K 10-Q · filed 2024-11-14 | -$1.87M derived: sum of 2 quarters · filed 2024-11-14 | -$4.80M 10-Q · filed 2024-11-14 | -$4.83M derived: sum of 4 quarters · filed 2024-11-14 | |||||
| 2023-06-30 | -$1.39M 10-Q · filed 2024-08-14 | -$4.31M 10-Q · filed 2024-08-14 | -$4.35M derived: sum of 3 quarters · filed 2024-08-14 | -$4.41M derived: sum of 4 quarters · filed 2024-08-14 | |||||
| 2023-03-31 | -$2.92M 10-Q · filed 2024-05-15 | -$2.96M derived: sum of 2 quarters · filed 2024-05-15 | -$3.02M derived: sum of 3 quarters · filed 2024-05-15 | -$3.02M derived: sum of 4 quarters · filed 2024-05-15 | |||||
| 2022-12-31 | -$38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$96.00K derived: sum of 2 quarters · filed 2024-03-26 | -$101.00K derived: sum of 3 quarters · filed 2024-03-26 | -$119.00K 10-K · filed 2024-03-26 | $19.00K 10-K · filed 2023-03-30 | ||||
| 2022-09-30 | -$58.00K 10-Q · filed 2023-11-01 | -$63.00K derived: sum of 2 quarters · filed 2023-11-01 | -$81.00K 10-Q · filed 2023-11-01 | $57.00K 10-Q · filed 2022-10-31 | |||||
| 2022-06-30 | -$5.00K 10-Q · filed 2023-08-07 | -$23.00K 10-Q · filed 2023-08-07 | $115.00M 10-Q · filed 2022-08-15 | ||||||
| 2022-03-31 | -$18.00K 10-Q · filed 2023-05-15 | $120.00M 10-Q · filed 2022-05-16 | |||||||
| 2021-12-31 | $138.00K 10-K · filed 2023-03-30 | $138.00M 10-K · filed 2022-03-28 | |||||||
| 2020-12-31 | $383.00M 10-K · filed 2022-03-28 | ||||||||
| 2020-07-28 | $200.00K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |